Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer

Cancer Epidemiology

Volumn 34, Issue 5, 2010, Pages 644-647

  Fang, Fang ^a   Valdimarsdóttir, Unnur ^a,b   Mucci, Lorelei ^b,c,d   Sparén, Pär ^a   Ye, Weimin ^a   Fall, Katja ^a,b,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ICELAND   (Iceland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

NSAIDs; Osteoarthritis; Prostate cancer specific mortality

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; DRUG USE; EARLY DIAGNOSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROSTATIC NEOPLASMS; REGISTRIES; SWEDEN;

EID: 77957240704     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.05.011     Document Type: Article

References (29)

1. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
2. Kim E.S., Hong W.K., Khuri F.R. Chemoprevention of aerodigestive tract cancers. Annu Rev Med 2002, 53:223-243.
3. Corley D.A., Kerlikowske K., Verma R., Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
4. Khuder S.A., Mutgi A.B. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001, 84:1188-1192.
5. De Marzo A.M., DeWeese T.L., Platz E.A., Meeker A.K., Nakayama M., Epstein J.I., et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004, 91:459-477.
6. Palapattu G.S., Sutcliffe S., Bastian P.J., Platz E.A., De Marzo A.M., Isaacs W.B., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005, 26:1170-1181.
7. Platz E.A., De Marzo A.M. Epidemiology of inflammation and prostate cancer. J Urol 2004, 171:S36-40.
8. Garcia Rodriguez L.A., Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:649-653.
9. Jacobs E.J., Rodriguez C., Mondul A.M., Connell C.J., Henley S.J., Calle E.E., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005, 97:975-980.
10. Perron L., Bairati I., Moore L., Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003, 106:409-415.
11. Mahmud S., Franco E., Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004, 90:93-99.
12. Pruthi R.S., Derksen J.E., Moore D., Carson C.C., Grigson G., Watkins C., et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006, 12:2172-2177.
13. Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006, 24:2723-2728.
14. Ausiello J.C., Stafford R.S. Trends in medication use for osteoarthritis treatment. J Rheumatol 2002, 29:999-1005.
15. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
16. Lunn M., McNeil D. Applying Cox regression to competing risks. Biometrics 1995, 51:524-532.
17. Hansson L.E., Nyren O., Hsing A.W., Bergström R., Josefsson S., Chow W.H., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996, 335:242-249.
18. Platz E.A., Rohrmann S., Pearson J.D., Corrada M.M., Watson D.J., De Marzo A.M., et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005, 14:390-396.
19. Singer E.A., Palapattu G.S., van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008, 113:2053-2057.
20. Jackson J.H., Gajewski E., Schraufstatter I.U., Hyslop P.A., Fuciarelli A.F., Cochrane C.G., et al. Damage to the bases in DNA induced by stimulated human neutrophils. J Clin Invest 1989, 84:1644-1649.
21. Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res 1990, 50:7415-7421.
22. Weitzman S.A., Weitberg A.B., Clark E.P., Stossel T.P. Phagocytes as carcinogens: malignant transformation produced by human neutrophils. Science 1985, 227:1231-1233.
23. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. Faseb J 1998, 12:1063-1073.
24. Leahy K.M., Koki A.T., Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000, 7:1163-1170.
25. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78.
26. Madaan S., Abel P.D., Chaudhary K.S., Hewitt R., Stott M.A., Stamp G.W., et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000, 86:736-741.
27. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000, 89:589-596.
28. Zha S., Gage W.R., Sauvageot J., Saria E.A., Putzi M.J., Ewing C.M., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001, 61:8617-8623.
29. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215:1-20.